However, since the end of the Cold War, as the North Atlantic Treaty Organization (NATO) has moved much of its defence focus "out of area", the Canadian military has also become more deeply engaged in international security operations in various other parts of the world most notably in Afghanistan since 2002.
If it is possible to answer this question, answer it for me (else, reply "unanswerable"): What does NTAO stand for?
Ah, so.. unanswerable

In general, USB cables have only plugs on their ends, while hosts and devices have only receptacles. Hosts almost universally have Type-A receptacles, while devices have one or another Type-B variety. Type-A plugs mate only with Type-A receptacles, and the same applies to their Type-B counterparts; they are deliberately physically incompatible. However, an extension to the USB standard specification called USB On-The-Go (OTG) allows a single port to act as either a host or a device, which is selectable by the end of the cable that plugs into the receptacle on the OTG-enabled unit. Even after the cable is hooked up and the units are communicating, the two units may "swap" ends under program control. This capability is meant for units such as PDAs in which the USB link might connect to a PC's host port as a device in one instance, yet connect as a host itself to a keyboard and mouse device in another instance.
If it is possible to answer this question, answer it for me (else, reply "unanswerable"): Devices usually have what type of receptacle?
Ah, so.. one or another Type-B variety

Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues.
If it is possible to answer this question, answer it for me (else, reply "unanswerable"): What enables a drug's owner to recover R&D costs?
Ah, so..
Patent protection